Rifabutin
Brand names: Mycobutin
Rifabutin is a rifamycin antibiotic used in the treatment and prevention of mycobacterial infections, including Mycobacterium avium complex and tuberculosis, often where rifampicin interactions are problematic.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing RNA synthesis and bacterial growth.
Prescribing in practice
- Rifabutin is a potent enzyme inducer with numerous clinically important drug interactions, including with antiretrovirals; review concomitant medicines carefully.
- It can cause uveitis, particularly at higher exposures or with interacting drugs that raise its levels.
- Like other rifamycins, it may cause a harmless orange-red discolouration of urine and other body fluids.
Monitoring
Monitor full blood count and liver function, and remain alert for visual symptoms suggesting uveitis.
Counselling the patient
- Your urine, tears and sweat may turn an orange-red colour, which is harmless and can stain soft contact lenses.
- Report any eye pain, redness or visual changes promptly.
- Tell any prescriber you take this medicine, as it interacts with many drugs.
Evidence & guidelines
Rifabutin is an established alternative to rifampicin where drug interactions are a concern, as reflected in UK tuberculosis and HIV guidance.
Reference: NICE NG33; BHIVA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023